Artivion (AORT) Competitors

Glaukos (NYSE:GKOS) and Artivion (NYSE:AORT) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Does the media favor GKOS or AORT?

In the previous week, Artivion had 21 more articles in the media than Glaukos. MarketBeat recorded 28 mentions for Artivion and 7 mentions for Glaukos. Glaukos' average media sentiment score of 1.06 beat Artivion's score of 0.51 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artivion	6 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, GKOS or AORT?

Glaukos has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.

Which has preferable earnings and valuation, GKOS or AORT?

Artivion has higher revenue and earnings than Glaukos. Artivion is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$383.48M	13.72	-$146.37M	-$1.65	-55.62
Artivion	$388.54M	5.32	-$13.36M	-$0.42	-104.26

Is GKOS or AORT more profitable?

Artivion has a net margin of -4.43% compared to Glaukos' net margin of -21.43%. Artivion's return on equity of 5.70% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-21.43%	-8.59%	-6.61%
Artivion	-4.43%	5.70%	2.29%

Do analysts prefer GKOS or AORT?

Glaukos presently has a consensus price target of $127.42, suggesting a potential upside of 38.84%. Artivion has a consensus price target of $39.80, suggesting a potential downside of 9.11%. Given Glaukos' higher possible upside, research analysts clearly believe Glaukos is more favorable than Artivion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Artivion	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do institutionals & insiders hold more shares of GKOS or AORT?

99.0% of Glaukos shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 5.8% of Glaukos shares are held by company insiders. Comparatively, 7.6% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Artivion beats Glaukos on 10 of the 16 factors compared between the two stocks.